Drug intelligence / Profile preview

UB-625a

Development stage: Preclinical
Lead developer: United BioPharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

UB-625a is a neutralizing monoclonal antibody developed by United Biopharma (UBP Asset) for the treatment and prevention of COVID-19. It is designed to target the spike protein of the SARS-CoV-2 virus, specifically blocking its interaction with the human angiotensin-converting enzyme 2 (ACE2) receptor to prevent viral entry into host cells. UB-625a is typically developed as part of a neutralizing antibody combination alongside UB-625b. Preclinical data suggests effectiveness against multiple SARS-CoV-2 variants, including those first identified in the UK, South Africa, Brazil, and India. As of the latest pipeline updates, the program remains in the preclinical stage of development.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on UB-625a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UB-625a.

Explore the full profile